SCHEMBL16053591

SCHEMBL16053591

Cc1cc(F)ccc1-n1c(-c2ccc(N3CCOCC3)nc2)nc2ccncc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ AOC3 Q16853 18/20 1.00
▸ KCNH2 Q12809 2/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16052876 0.91 KCNH2 (0.86) AOC3KCNH2
SCHEMBL16053336 0.90 AOC3 (0.81) AOC3KCNH2
SCHEMBL16052757 0.89 AOC3 (0.81) AOC3KCNH2
SCHEMBL17611242 0.88 AOC3 (0.85) AOC3KCNH2
SCHEMBL16053258 0.88 KCNH2 (1.00) AOC3KCNH2
SCHEMBL30026916 0.86 AOC3 (1.00) AOC3KCNH2
SCHEMBL16047562 0.86 AOC3 (1.00) AOC3KCNH2
SCHEMBL16052914 0.85 KCNH2 (0.79) AOC3KCNH2
SCHEMBL16052995 0.85 AOC3 (1.00) AOC3KCNH2
SCHEMBL16053450 0.82 AOC3 (0.83) AOC3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 — — US claimed
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC (US) 2020-11-05 — — US claimed
US-20200147059-A1 NEW THERAPEUTIC USES OF ENZYME INHIBITORS PROXIMAGEN, LLC (US) 2020-05-14 — — US claimed
EP-3634393-A1 INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE PROXIMAGEN, LLC (US) 2020-04-15 — — EP claimed
US-10428066-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2019-10-01 — — US claimed
EP-2970260-B1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN LLC (US) 2019-04-24 — — EP claimed
WO-2018224837-A1 INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE Proximagen Group Limited (GB) 2018-12-13 — — WO claimed
US-9676769-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN LIMITED (GB) 2017-06-13 — — US claimed
EP-2970260-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS Proximagen Limited (GB) 2016-01-20 — — EP claimed
WO-2014140592-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN LIMITED (GB) 2014-09-18 — — WO claimed
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 — — US disclosed
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 — — US disclosed
EP-3777846-A1 VAP-1 INHIBITORS FOR TREATING PAIN BenevolentAI Cambridge Limited (GB) 2021-02-17 — — EP disclosed
EP-3777846-A1 VAP-1 INHIBITORS FOR TREATING PAIN BenevolentAI Cambridge Limited (GB) 2021-02-17 — — EP disclosed
US-20200397764-A1 VAP-1 INHIBITORS FOR TREATING PAIN PROXIMAGEN, LLC 2020-12-24 — — US disclosed
US-20160046622-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC 2016-02-18 — — US disclosed
WO-2015189534-A1 VAP-1 INHIBITORS FOR TREATING MUSCULAR DYSTROPHY PROXIMAGEN LIMITED (GB) 2015-12-17 — — WO disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 — — US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 — — US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200397764-A1 VAP-1 INHIBITORS FOR TREATING PAIN VAPB, VAPA, OPRL1 AOC3 55/4885KCNH2 1764/4885
US-10428066-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PNPO, SSB, XDH AOC3 10/4885KCNH2 364/4885
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PNPO, PPOX, SCO2 AOC3 7/4885KCNH2 448/4885
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, PPOX, SCO2 AOC3 7/4885KCNH2 448/4885
US-20160046622-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, AOC3, IL4I1 AOC3 2/4885KCNH2 570/4885
US-20200147059-A1 NEW THERAPEUTIC USES OF ENZYME INHIBITORS VAPB, VAPA, SMOX AOC3 4/4885KCNH2 1505/4885
US-20150258101-A1 NEW COMPOUNDS AOX1, QSOX1, MAOB AOC3 85/4885KCNH2 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback